Announcements Trials
Browse Landscape

Status

No longer available 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 580Observational 9Expanded_access 3

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Everolimus × Clear all
NCT03493152 2025-05-28

Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)

The University of Texas Health Science Center at San Antonio

No longer available
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05108740 2021-12-09

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Novartis

No longer available
Breast

Breast Neoplasms

NCT00655252 2011-08-19

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Novartis

No longer available
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡